Venker Eric's Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Dec 11, 2025
- Accession no.
- 0001140361-25-045279
- Filed
- Dec 11, 2025
- Trade date
- Dec 9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.17M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Venker EricCIK 0001801917 | Officer (President & Immunovant CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | Common Shares | MOption exerciseAcquired | +200,000 | $3.85 | +$770,000 | 1,697,908 | Direct | |
| Dec 9, 2025 | Common Shares | SSaleDisposed | −200,000 | $20.85 | −$4,170,000 | 1,497,908 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | Common Stock | MOption exerciseDisposed | −200,000 | $0.00 | $0 | 5,876,523 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.